BioSpace News Archive

Patients treated with Agenus’ PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses

TWi Biotechnology, Inc. today announced that it has enrolled the first patient in a phase 2 trial of AC-203 for the treatment of inherited Epidermolysis Bullosa (EB).

Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer

Dr. Barnard Will Receive the Distinguished Service Award

Results presented today demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment

Results shared at ACR/ARHP annual meeting highlight non-invasive therapy reduces pain and fatigue associated with lupus

Study findings presented at the largest rheumatology meeting in the U.S. signal that people with arthritis may soon have information on overall outcome on a medication from a measure that combines the range of possible benefits and the full spectrum of potential side effects at the individual patient level.